Historical Valuation
Vivos Therapeutics Inc (VVOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.84 is considered Fairly compared with the five-year average of -2.57. The fair price of Vivos Therapeutics Inc (VVOS) is between 2.21 to 3.80 according to relative valuation methord.
Relative Value
Fair Zone
2.21-3.80
Current Price：2.22
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Vivos Therapeutics Inc (VVOS) has a current Price-to-Book (P/B) ratio of 8.26. Compared to its 3-year average P/B ratio of 24.87 , the current P/B ratio is approximately -66.79% higher. Relative to its 5-year average P/B ratio of 16.25, the current P/B ratio is about -49.18% higher. Vivos Therapeutics Inc (VVOS) has a Forward Free Cash Flow (FCF) yield of approximately -67.57%. Compared to its 3-year average FCF yield of -126.26%, the current FCF yield is approximately -46.48% lower. Relative to its 5-year average FCF yield of -94.94% , the current FCF yield is about -28.83% lower.
P/B
Median3y
24.87
Median5y
16.25
FCF Yield
Median3y
-126.26
Median5y
-94.94
Competitors Valuation Multiple
AI Analysis for VVOS
The average P/S ratio for VVOS competitors is 0.91, providing a benchmark for relative valuation. Vivos Therapeutics Inc Corp (VVOS.O) exhibits a P/S ratio of 0.84, which is -7.56% above the industry average. Given its robust revenue growth of 75.73%, this premium appears sustainable.
Performance Decomposition
AI Analysis for VVOS
1Y
3Y
5Y
Market capitalization of VVOS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of VVOS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is VVOS currently overvalued or undervalued?
Vivos Therapeutics Inc (VVOS) is now in the Fair zone, suggesting that its current forward PS ratio of 0.84 is considered Fairly compared with the five-year average of -2.57. The fair price of Vivos Therapeutics Inc (VVOS) is between 2.21 to 3.80 according to relative valuation methord.
What is Vivos Therapeutics Inc (VVOS) fair value?
VVOS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Vivos Therapeutics Inc (VVOS) is between 2.21 to 3.80 according to relative valuation methord.
How does VVOS's valuation metrics compare to the industry average?
The average P/S ratio for VVOS's competitors is 0.91, providing a benchmark for relative valuation. Vivos Therapeutics Inc Corp (VVOS) exhibits a P/S ratio of 0.84, which is -7.56% above the industry average. Given its robust revenue growth of 75.73%, this premium appears sustainable.
What is the current P/B ratio for Vivos Therapeutics Inc (VVOS) as of Jan 09 2026?
As of Jan 09 2026, Vivos Therapeutics Inc (VVOS) has a P/B ratio of 8.26. This indicates that the market values VVOS at 8.26 times its book value.
What is the current FCF Yield for Vivos Therapeutics Inc (VVOS) as of Jan 09 2026?
As of Jan 09 2026, Vivos Therapeutics Inc (VVOS) has a FCF Yield of -67.57%. This means that for every dollar of Vivos Therapeutics Inc’s market capitalization, the company generates -67.57 cents in free cash flow.
What is the current Forward P/E ratio for Vivos Therapeutics Inc (VVOS) as of Jan 09 2026?
As of Jan 09 2026, Vivos Therapeutics Inc (VVOS) has a Forward P/E ratio of -1.51. This means the market is willing to pay $-1.51 for every dollar of Vivos Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Vivos Therapeutics Inc (VVOS) as of Jan 09 2026?
As of Jan 09 2026, Vivos Therapeutics Inc (VVOS) has a Forward P/S ratio of 0.84. This means the market is valuing VVOS at $0.84 for every dollar of expected revenue over the next 12 months.